Novo Nordisk reports Q3 earnings and asset impairments
Novo Nordisk reported its third-quarter 2026 results, with adjusted operating profit increasing by 27% to 31.72 billion Danish kroner (DKK). However, reported operating profit fell by 9% due to 8.7 billion DKK in asset impairment charges, reflecting costs for manufacturing reorganization and the development of ziltivekimab.
Key points
- The company's reported operating profit for the third quarter of 2026 fell by 9% year-over-year.
- The oral Wegovy pill showed strong demand, generating 5.39 billion DKK in revenue during the third quarter of 2026.
- As of November 2, 2026, Novo Nordisk is continuing its share repurchase program initiated on May 6, 2026.
Financial results and asset impairments
The company's reported operating profit for the third quarter of 2026 fell by 9% year-over-year. This figure includes non-cash impairment charges: 4.6 billion DKK related to the ziltivekimab project and 4.1 billion DKK for manufacturing network optimization.
Portfolio development and clinical trials
The oral Wegovy pill showed strong demand, generating 5.39 billion DKK in revenue during the third quarter of 2026. Total prescriptions for the drug have exceeded 8 million since its launch.
Clinical trial results were mixed: CagriSema showed success in the REDEFINE 9 and REIMAGINE 5 studies. Meanwhile, the ZEUS and HERMES trials for ziltivekimab did not meet primary endpoints, while the HIBISCUS trial for Etavopivat was successfully completed.
Share repurchases
As of November 2, 2026, Novo Nordisk is continuing its share repurchase program initiated on May 6, 2026. Since February 4, 2026, the company has repurchased 41,714,179 B shares for a total of 11.56 billion DKK.
Key focus areas
Investors should monitor future financial reports to see if additional manufacturing reorganization costs emerge, which could impact future earnings.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Novo Nordisk A S
A notification in your browser or on your phone when we publish about Novo Nordisk A S. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
